NCT00018018View on ClinicalTrials.gov

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2001

Study Completion Date

September 17, 2014

Conditions

Severe Combined Immunodeficiency Syndrome

Interventions

DRUG

CD34+ cells transduced with ADA retrovir

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Human Genome Research Institute (NHGRI)

NIH

NCT00018018 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency | Biotech Hunter | Biotech Hunter